Novavax (NVAX) could be the COVID-19 vaccine winner every investor is searching for
Novavax is a small-cap company with huge potential in the vaccine industry. The company has seen gains of 500% in just the past year with word that they are the likely winner facing the need for a COVID-19 vaccine. This makes investors hopeful that the company will make a fortune off the potential vaccine. Novavax mainly focuses on the creation of vaccines, they, however, do not have any products in the market as of now but the company has a potential flu vaccine called NanoFlu, which is being developed specifically for adults over the age of 65. Sure there are other companies currently developing vaccines, however, Novavax argues that its NanoFlu has a chance to be more effective than some of the current market leaders. There was recently a clinical trial pitting NanoFlu against Sanofi’s flu vaccine Fluzone HD. Sanofi’s flu vaccine is currently the leading flu vaccine for older adults, however NanoFlu “demonstrated significantly stronger and broader immune responses” against various strains of the flu.
Novavax, which had prior experience dealing with other strands of coronaviruses, was able to identify an antibody that could be effective against the SARS-CoV-2 virus that causes COVID-19. The companies vaccine candidate named NVX-CoV2373 demonstrated high immunogenicity in preclinical trials. Novavax also claimed that NVX-CoV2373 generated effective antibodies against SARS-CoV-2 in preclinical trials. The company aims to begin human trials mid-May with the hope that they can successfully develop a vaccine to fight off COVID-19.
Novavax, Inc. operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm’s vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.